Ezetimibe/rosuvastatin

Ezetimibe/rosuvastatin
Ezetimibe (top) and rosuvastatin (bottom)
Combination of
EzetimibeHypolipidemic agent
RosuvastatinStatin
Clinical data
Trade namesRidutrink, Roszet, others
AHFS/Drugs.comMultum Consumer Information
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol.[6][7] In some countries it is sold as a kit or a pack containing two distinct pills.[8][9]

The combination was approved for medical use in the United States in March 2021.[4]

  1. ^ a b "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 29 March 2022. Retrieved 25 March 2021.
  2. ^ "EZESTAT COMPOSITE PACK (Pharmacor Pty Ltd)". Department of Health and Aged Care. Archived from the original on 18 March 2023.
  3. ^ Cite error: The named reference Roszet FDA label was invoked but never defined (see the help page).
  4. ^ a b "Roszet: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 24 March 2021.
  5. ^ "Ezetimibe/rosuvastatin: List of nationally authorised medicinal products" (PDF). European Medicines Agency (EMA). 21 March 2018. PSUSA/00010271/201707. Retrieved 17 February 2020.
  6. ^ "Ridutrin SmPC" (PDF). Medicines Data Bank. 30 May 2019. Archived (PDF) from the original on 18 February 2020. Retrieved 17 February 2020.
  7. ^ Willihnganz MJ, Gurevitz SL, Clayton BD (November 2021). "HMG-CoA Reductase Inhibitor Combination Products". Clayton's Basic Pharmacology for Nurses - E-Book. Elsevier Health Sciences. p. 344. ISBN 978-0-323-81258-0.
  8. ^ "Rosuzet Composite Pack". NPS MedicineWise. 8 January 2020. Archived from the original on 18 February 2020. Retrieved 17 February 2020.
  9. ^ "Rosuvastatin international". Drugs.com. 3 February 2020. Archived from the original on 18 February 2020. Retrieved 17 February 2020.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.